Michael P Arnold1, Michele Andrasik, Stewart Landers, Shelly Karuna, Matthew J Mimiaga, Steven Wakefield, Kenneth Mayer, Susan Buchbinder, Beryl A Koblin. 1. Michael P. Arnold, Michele Andrasik, Shelly Karuna, and Steven Wakefield are with the Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA. Stewart Landers is with Boston Health Services, John Snow Inc., Boston, MA. Matthew J. Mimiaga is with the Department of Epidemiology, Harvard School of Public Health, Cambridge, MA. Kenneth Mayer is with the Department of Global Health and Population, Harvard School of Public Health. Susan Buchbinder is with Bridge HIV, San Francisco Department of Public Health, San Francisco, CA. Beryl A. Koblin is with Project Achieve, New York Blood Center, New York, NY.
Abstract
OBJECTIVES: We explored the relative effects of 2 awareness components-exposure and attention-on racial/ethnic differences in HIV vaccine trial awareness among men who have sex with men (MSM). METHODS: Surveys assessing awareness of and attitudes toward HIV vaccine trials were administered to 1723 MSM in 6 US cities. Proxy measures of exposure included use of HIV resources and other health care services, community involvement, income, and residence. Attention proxy measures included research attitudes, HIV susceptibility, and HIV message fatigue. Using logistic regression models, we assessed the extent to which these proxies accounted for racial/ethnic differences in vaccine trial awareness. RESULTS: White MSM reported significantly (P < .01) higher rates of HIV vaccine trial awareness (22%) compared with Latino (17%), Black (13%) and "other" (13%) MSM. Venue-based exposure proxies and research-directed attitudinal attention proxies were significantly associated with awareness, but only accounted for the White-Latino disparity in awareness. No proxies accounted for the White-Black or White-"other" differentials in awareness. CONCLUSIONS: Sources of disparities in awareness of HIV vaccine trials remain to be explained. Future trials seeking to promote diverse participation should explore additional exposure and attention mediators.
OBJECTIVES: We explored the relative effects of 2 awareness components-exposure and attention-on racial/ethnic differences in HIV vaccine trial awareness among men who have sex with men (MSM). METHODS: Surveys assessing awareness of and attitudes toward HIV vaccine trials were administered to 1723 MSM in 6 US cities. Proxy measures of exposure included use of HIV resources and other health care services, community involvement, income, and residence. Attention proxy measures included research attitudes, HIV susceptibility, and HIV message fatigue. Using logistic regression models, we assessed the extent to which these proxies accounted for racial/ethnic differences in vaccine trial awareness. RESULTS: White MSM reported significantly (P < .01) higher rates of HIV vaccine trial awareness (22%) compared with Latino (17%), Black (13%) and "other" (13%) MSM. Venue-based exposure proxies and research-directed attitudinal attention proxies were significantly associated with awareness, but only accounted for the White-Latino disparity in awareness. No proxies accounted for the White-Black or White-"other" differentials in awareness. CONCLUSIONS: Sources of disparities in awareness of HIV vaccine trials remain to be explained. Future trials seeking to promote diverse participation should explore additional exposure and attention mediators.
Authors: Ron Stall; Thomas C Mills; John Williamson; Trevor Hart; Greg Greenwood; Jay Paul; Lance Pollack; Diane Binson; Dennis Osmond; Joseph A Catania Journal: Am J Public Health Date: 2003-06 Impact factor: 9.308
Authors: Kelly A Gebo; John A Fleishman; Richard Conviser; Erin D Reilly; P Todd Korthuis; Richard D Moore; James Hellinger; Philip Keiser; Haya R Rubin; Lawrence Crane; Fred J Hellinger; W Christopher Mathews Journal: J Acquir Immune Defic Syndr Date: 2005-01-01 Impact factor: 3.731
Authors: Stephen R Cole; Miguel A Hernán; James M Robins; Kathryn Anastos; Joan Chmiel; Roger Detels; Carolyn Ervin; Joseph Feldman; Ruth Greenblatt; Lawrence Kingsley; Shenghan Lai; Mary Young; Mardge Cohen; Alvaro Muñoz Journal: Am J Epidemiol Date: 2003-10-01 Impact factor: 4.897
Authors: Peter W Hunt; Steven G Deeks; Benigno Rodriguez; Hernan Valdez; Starley B Shade; Donald I Abrams; Mari M Kitahata; Melissa Krone; Torsten B Neilands; Richard J Brand; Michael M Lederman; Jeffrey N Martin Journal: AIDS Date: 2003-09-05 Impact factor: 4.177
Authors: Carol E Golin; Honghu Liu; Ron D Hays; Loren G Miller; C Keith Beck; Jeanette Ickovics; Andrew H Kaplan; Neil S Wenger Journal: J Gen Intern Med Date: 2002-10 Impact factor: 5.128
Authors: Audrey Harkness; Brooke G Rogers; Raymond Balise; Daniel Mayo; Elliott R Weinstein; Steven A Safren; John E Pachankis Journal: AIDS Behav Date: 2021-01-23